Demir, Enver AhmetÖz, MehmetAlp, Muhammed İkbalGergerlioğlu, Hasan SerdarAtalık, Kısmet Esra NurullahoğluYerlikaya, Fatma Hümeyra2020-03-262020-03-2620160006-92481336-0345https://dx.doi.org/10.4149/BLL_2016_021https://hdl.handle.net/20.500.12395/33363OBJECTIVES: Cisplatin (cis-diamminedichloroplatinum (II)) is a widely-used platinum-based chemotherapeutic agent which has dose-limiting side-effects. Also, the drug resistance is another instance that decreases treatment success in cisplatin chemotherapy. The growing body of evidence suggests that curcumin, a polyphenolic compound extracted from the spice turmeric, may exert synergistic effects and sensitize malign cells to cisplatin, while alleviating cytotoxicity-related side-effects. The present study was aimed to investigate mood-associated interactions between cisplatin and curcumin. MATERIALS AND METHODS: Thirty-four adult male Wistar albino rats were randomly assigned to four groups as control, curcumin (300 mg/kg/day, p.o. for 5 weeks), cisplatin (5 mg/kg/week, i.p. for 5 weeks), and curcumin plus cisplatin (same doses as above). The open field, elevated plus maze, and forced swim tests were engaged to evaluate mood-associated behaviors. RESULTS: We demonstrated that depression- and anxiety-like behaviors were not altered by the administration of curcumin along with the chronic cisplatin treatment. CONCLUSION: According to the results of the present study, we concluded that curcumin might be regarded as a safe adjuvant in cisplatin chemotherapy in terms of the mood-associated behaviors (Fig. 4, Ref 41).en10.4149/BLL_2016_021info:eu-repo/semantics/openAccesscisplatincurcumindepressionanxietylocomotionexplorationArticle117210611126830042Q3WOS:000371751300009Q3